Vercauteren Jurgen, Wensing Annemarie M J, van de Vijver David A M C, Albert Jan, Balotta Claudia, Hamouda Osamah, Kücherer Claudia, Struck Daniel, Schmit Jean-Claude, Asjö Birgitta, Bruckova Marie, Camacho Ricardo J, Clotet Bonaventura, Coughlan Suzie, Grossman Zehava, Horban Andrzej, Korn Klaus, Kostrikis Leondios, Nielsen Claus, Paraskevis Dimitrios, Poljak Mario, Puchhammer-Stöckl Elisabeth, Riva Chiara, Ruiz Lidia, Salminen Mika, Schuurman Rob, Sonnerborg Anders, Stanekova Danica, Stanojevic Maja, Vandamme Anne-Mieke, Boucher Charles A B
Katholieke Universiteit Leuven, Leuven, Belgium.
J Infect Dis. 2009 Nov 15;200(10):1503-8. doi: 10.1086/644505.
The SPREAD Programme investigated prospectively the time trend from September 2002 through December 2005 of transmitted drug resistance (TDR) among 2793 patients in 20 European countries and in Israel with newly diagnosed human immunodeficiency virus type 1 (HIV-1) infection. The overall prevalence of TDR was 8.4% (225 of 2687 patients; 95% confidence interval [CI], 7.4%-9.5%), the prevalence of nucleoside reverse-transcriptase inhibitor (NRTI) resistance was 4.7% (125 of 2687 patients; 95% CI, 3.9%-5.5%), the prevalence of nonucleoside reverse-transcriptase inhibitor (NNRTI) resistance was 2.3% (62 of 2687 patients; 95% CI, 1.8%-2.9%), and the prevalence of protease inhibitor (PI) resistance was 2.9% (79 of 2687 patients; 95% CI, 2.4%-3.6%). There was no time trend in the overall TDR or in NRTI resistance, but there was a statistically significant decrease in PI resistance (P = .04) and in NNRTI resistance after an initial increase (P = .02). We found that TDR appears to be stabilizing in Europe, consistent with recent reports of decreasing drug resistance and improved viral suppression in patients treated for HIV-1 infection.
“传播”项目前瞻性地调查了2002年9月至2005年12月期间，20个欧洲国家和以色列的2793例新诊断为1型人类免疫缺陷病毒（HIV-1）感染患者的传播耐药性（TDR）的时间趋势。TDR的总体患病率为8.4%（2687例患者中的225例；95%置信区间[CI]，7.4%-9.5%），核苷类逆转录酶抑制剂（NRTI）耐药性的患病率为4.7%（2687例患者中的125例；95%CI，3.9%-5.5%），非核苷类逆转录酶抑制剂（NNRTI）耐药性的患病率为2.3%（2687例患者中的62例；95%CI，1.8%-2.9%），蛋白酶抑制剂（PI）耐药性的患病率为2.9%（2687例患者中的79例；95%CI，2.4%-3.6%）。总体TDR或NRTI耐药性没有时间趋势，但PI耐药性有统计学显著下降（P = .04），NNRTI耐药性在最初上升后有统计学显著下降（P = .02）。我们发现，欧洲的TDR似乎趋于稳定，这与最近关于HIV-1感染患者耐药性降低和病毒抑制改善的报告一致。
